SE503482C2 - Användning av 17-ketosteroider, eventuellt åtföljande eller i kombination med ett immunomoduleringsmedel eller ett antiviralt medel, för framställning av ett läkemedel för användning vid profylax och terapi av en retroviral infektion - Google Patents

Användning av 17-ketosteroider, eventuellt åtföljande eller i kombination med ett immunomoduleringsmedel eller ett antiviralt medel, för framställning av ett läkemedel för användning vid profylax och terapi av en retroviral infektion

Info

Publication number: SE503482C2
Authority: SE; Sweden
Prior art keywords: compound; hiv; infection; prophylaxis; therapy
Prior art date: 1987-04-16

Application number

SE8801406A

Other languages

English (en)

Swedish (sv)

Other versions

SE8801406D0 (sv

SE8801406L (sv

Inventor

Patrick Thomas Prendergast

Original Assignee

Colthurst Ltd

Patrick Thomas Prendergast

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-04-16

Filing date

1988-04-15

Publication date

1996-06-24

1988-04-15 Application filed by Colthurst Ltd, Patrick Thomas Prendergast filed Critical Colthurst Ltd

1988-04-15 Publication of SE8801406D0 publication Critical patent/SE8801406D0/xx

1988-10-17 Publication of SE8801406L publication Critical patent/SE8801406L/xx

1996-06-24 Publication of SE503482C2 publication Critical patent/SE503482C2/sv

Links

238000011321 prophylaxis Methods 0.000 title claims abstract description 17
238000002560 therapeutic procedure Methods 0.000 title claims abstract description 17
239000003443 antiviral agent Substances 0.000 title claims abstract description 12
206010038997 Retroviral infections Diseases 0.000 title claims abstract description 11
239000003814 drug Substances 0.000 title claims description 30
239000003795 chemical substances by application Substances 0.000 title claims description 19
230000002519 immonomodulatory effect Effects 0.000 title claims description 15
238000004519 manufacturing process Methods 0.000 title description 11
150000001875 compounds Chemical class 0.000 claims abstract description 85
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 13
239000001257 hydrogen Substances 0.000 claims abstract description 13
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 8
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
150000008134 glucuronides Chemical group 0.000 claims abstract description 4
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 3
229910052708 sodium Inorganic materials 0.000 claims abstract description 3
208000030507 AIDS Diseases 0.000 claims description 32
FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims description 21
FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 claims description 20
229960002847 prasterone Drugs 0.000 claims description 20
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 14
208000031886 HIV Infections Diseases 0.000 claims description 12
208000037357 HIV infectious disease Diseases 0.000 claims description 12
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 12
229960002555 zidovudine Drugs 0.000 claims description 12
238000002360 preparation method Methods 0.000 claims description 10
CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 claims description 7
229950009829 prasterone sulfate Drugs 0.000 claims description 7
229940079322 interferon Drugs 0.000 claims description 5
208000011580 syndromic disease Diseases 0.000 claims description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 claims description 4
ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims description 4
238000007910 systemic administration Methods 0.000 claims description 4
YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 claims description 3
CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 claims description 3
-1 Castanospermin Chemical compound 0.000 claims description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims description 3
229930182480 glucuronide Chemical group 0.000 claims description 3
229960000885 rifabutin Drugs 0.000 claims description 3
239000004322 Butylated hydroxytoluene Substances 0.000 claims description 2
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
108010036949 Cyclosporine Proteins 0.000 claims description 2
IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 claims description 2
229920001503 Glucan Polymers 0.000 claims description 2
239000004378 Glycyrrhizin Substances 0.000 claims description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
108090000467 Interferon-beta Proteins 0.000 claims description 2
102000003996 Interferon-beta Human genes 0.000 claims description 2
102000000589 Interleukin-1 Human genes 0.000 claims description 2
108010002352 Interleukin-1 Proteins 0.000 claims description 2
108010002350 Interleukin-2 Proteins 0.000 claims description 2
102000000588 Interleukin-2 Human genes 0.000 claims description 2
229920001491 Lentinan Polymers 0.000 claims description 2
YFGBQHOOROIVKG-FKBYEOEOSA-N Met-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-FKBYEOEOSA-N 0.000 claims description 2
108010042237 Methionine Enkephalin Proteins 0.000 claims description 2
235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 2
235000003140 Panax quinquefolius Nutrition 0.000 claims description 2
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 2
229930003270 Vitamin B Natural products 0.000 claims description 2
235000010323 ascorbic acid Nutrition 0.000 claims description 2
229960005070 ascorbic acid Drugs 0.000 claims description 2
239000011668 ascorbic acid Substances 0.000 claims description 2
229950009494 bropirimine Drugs 0.000 claims description 2
235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 2
229940095259 butylated hydroxytoluene Drugs 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims description 2
229960001265 ciclosporin Drugs 0.000 claims description 2
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 2
229960001380 cimetidine Drugs 0.000 claims description 2
229930182912 cyclosporin Natural products 0.000 claims description 2
229960000633 dextran sulfate Drugs 0.000 claims description 2
229960005102 foscarnet Drugs 0.000 claims description 2
IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 claims description 2
229960004675 fusidic acid Drugs 0.000 claims description 2
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 2
235000008434 ginseng Nutrition 0.000 claims description 2
LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 2
229960004949 glycyrrhizic acid Drugs 0.000 claims description 2
UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 2
235000019410 glycyrrhizin Nutrition 0.000 claims description 2
LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims description 2
229940115286 lentinan Drugs 0.000 claims description 2
108010001062 polysaccharide-K Proteins 0.000 claims description 2
229960000329 ribavirin Drugs 0.000 claims description 2
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 2
ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 claims description 2
239000011734 sodium Chemical group 0.000 claims description 2
ZTEPAMQURYRDPM-UHFFFAOYSA-M sodium;n,n-diethylcarbamothioate Chemical compound [Na+].CCN(CC)C([O-])=S ZTEPAMQURYRDPM-UHFFFAOYSA-M 0.000 claims description 2
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 claims description 2
229960005314 suramin Drugs 0.000 claims description 2
PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 claims description 2
NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 claims description 2
229960001099 trimetrexate Drugs 0.000 claims description 2
235000019156 vitamin B Nutrition 0.000 claims description 2
239000011720 vitamin B Substances 0.000 claims description 2
229960000523 zalcitabine Drugs 0.000 claims description 2
102000006992 Interferon-alpha Human genes 0.000 claims 3
108010047761 Interferon-alpha Proteins 0.000 claims 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
229910052794 bromium Chemical group 0.000 claims 2
CWVMWSZEMZOUPC-JUAXIXHSSA-N (3s,5s,8r,9s,10s,13s,14s,16r)-16-bromo-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C([C@H](Br)C4)=O)[C@@H]4[C@@H]3CC[C@H]21 CWVMWSZEMZOUPC-JUAXIXHSSA-N 0.000 claims 1
KOYMTVWMCXDJNV-UHFFFAOYSA-N 1-[(2-methoxy-6-methylpyridin-3-yl)methyl]aziridine-2-carbonitrile Chemical compound COC1=NC(C)=CC=C1CN1C(C#N)C1 KOYMTVWMCXDJNV-UHFFFAOYSA-N 0.000 claims 1
WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 claims 1
229930183010 Amphotericin Natural products 0.000 claims 1
QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 claims 1
241000208340 Araliaceae Species 0.000 claims 1
108010071942 Colony-Stimulating Factors Proteins 0.000 claims 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
AXDLCFOOGCNDST-UHFFFAOYSA-N N-methyl-DL-tyrosine Natural products CNC(C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-UHFFFAOYSA-N 0.000 claims 1
102400000160 Thymopentin Human genes 0.000 claims 1
101800001703 Thymopentin Proteins 0.000 claims 1
108010046075 Thymosin Proteins 0.000 claims 1
102000007501 Thymosin Human genes 0.000 claims 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
229940009444 amphotericin Drugs 0.000 claims 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical group O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims 1
125000001246 bromo group Chemical group Br* 0.000 claims 1
229940087451 cytovene Drugs 0.000 claims 1
VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 claims 1
229960002759 eflornithine Drugs 0.000 claims 1
150000004702 methyl esters Chemical class 0.000 claims 1
230000002992 thymic effect Effects 0.000 claims 1
229960004517 thymopentin Drugs 0.000 claims 1
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims 1
108700016958 thymosin fraction 5 Proteins 0.000 claims 1
230000002916 thymostimulin Effects 0.000 claims 1
229960003873 thymostimulin Drugs 0.000 claims 1
208000015181 infectious disease Diseases 0.000 abstract description 38
241000725303 Human immunodeficiency virus Species 0.000 abstract 1
239000002955 immunomodulating agent Substances 0.000 abstract 1
229940121354 immunomodulator Drugs 0.000 abstract 1
125000004436 sodium atom Chemical group 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 56
210000002540 macrophage Anatomy 0.000 description 53
230000005764 inhibitory process Effects 0.000 description 22
239000000427 antigen Substances 0.000 description 20
108091007433 antigens Proteins 0.000 description 20
102000036639 antigens Human genes 0.000 description 20
229940079593 drug Drugs 0.000 description 20
230000015572 biosynthetic process Effects 0.000 description 19
238000012360 testing method Methods 0.000 description 19
241000700605 Viruses Species 0.000 description 17
230000000694 effects Effects 0.000 description 16
101710205625 Capsid protein p24 Proteins 0.000 description 14
101710177166 Phosphoprotein Proteins 0.000 description 14
101710149279 Small delta antigen Proteins 0.000 description 14
102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 14
210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 13
230000000840 anti-viral effect Effects 0.000 description 13
210000001744 T-lymphocyte Anatomy 0.000 description 11
238000002474 experimental method Methods 0.000 description 11
210000004369 blood Anatomy 0.000 description 10
239000008280 blood Substances 0.000 description 10
108010027044 HIV Core Protein p24 Proteins 0.000 description 9
206010025323 Lymphomas Diseases 0.000 description 9
230000001154 acute effect Effects 0.000 description 9
230000014509 gene expression Effects 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
230000000120 cytopathologic effect Effects 0.000 description 8
210000001616 monocyte Anatomy 0.000 description 8
238000000338 in vitro Methods 0.000 description 7
210000004698 lymphocyte Anatomy 0.000 description 7
238000000034 method Methods 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
238000011282 treatment Methods 0.000 description 7
239000004480 active ingredient Substances 0.000 description 6
210000000987 immune system Anatomy 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 6
231100000419 toxicity Toxicity 0.000 description 6
230000001988 toxicity Effects 0.000 description 6
238000004458 analytical method Methods 0.000 description 5
230000002458 infectious effect Effects 0.000 description 5
239000000825 pharmaceutical preparation Substances 0.000 description 5
239000002552 dosage form Substances 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
238000011002 quantification Methods 0.000 description 4
238000011160 research Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
102100031126 6-phosphogluconolactonase Human genes 0.000 description 3
108010029731 6-phosphogluconolactonase Proteins 0.000 description 3
229940126062 Compound A Drugs 0.000 description 3
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 3
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
108010007843 NADH oxidase Proteins 0.000 description 3
108010047620 Phytohemagglutinins Proteins 0.000 description 3
CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 description 3
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
230000001885 phytohemagglutinin Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
201000000596 systemic lupus erythematosus Diseases 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
206010000807 Acute HIV infection Diseases 0.000 description 2
108010041397 CD4 Antigens Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
229920006362 Teflon® Polymers 0.000 description 2
108010067390 Viral Proteins Proteins 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
238000002832 anti-viral assay Methods 0.000 description 2
238000003556 assay Methods 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000004566 building material Substances 0.000 description 2
239000006071 cream Substances 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
230000006866 deterioration Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
239000000499 gel Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
229910001385 heavy metal Inorganic materials 0.000 description 2
230000000652 homosexual effect Effects 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
229960001438 immunostimulant agent Drugs 0.000 description 2
239000003022 immunostimulating agent Substances 0.000 description 2
230000003308 immunostimulating effect Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000010076 replication Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
XOYXESIZZFUVRD-YGGZJJQXSA-N (2S,3S,4R,5S,6R)-6-[(2R,3R,4R,5S,6S)-6-[(2R,3S,4S,5S,6S)-5-acetamido-6-[(2R,3R,4R,5S,6S)-4-acetyloxy-6-[(2R,3R,4R,5S,6S)-4-acetyloxy-6-[(2R,3R,4R,5S,6R)-4-acetyloxy-5-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxy-5-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-5-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-acetyloxy-5-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-acetyloxy-3-[(2S,3S,4R,5R,6R)-4-acetyloxy-5-[(2S,3S,4R,5R,6R)-4-acetyloxy-3-hydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxyoxane-2-carboxylic acid Polymers CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@H](CO)[C@@H](O[C@@H]4O[C@H](CO)[C@@H](O[C@@H]5O[C@H](CO)[C@@H](O[C@@H]6O[C@@H]([C@@H](O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](CO)[C@@H](OC)[C@H](OC(C)=O)[C@@H]8O)[C@H](OC(C)=O)[C@@H]7O)[C@H](OC(C)=O)[C@@H]6O)C(O)=O)[C@H](OC(C)=O)[C@@H]5O)[C@@H](O)[C@@H]4NC(C)=O)[C@H](OC(C)=O)[C@@H]3O)[C@H](OC(C)=O)[C@@H]2O)[C@H](OC(C)=O)[C@@H]1O XOYXESIZZFUVRD-YGGZJJQXSA-N 0.000 description 1
241000427202 Adria Species 0.000 description 1
206010054196 Affect lability Diseases 0.000 description 1
101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
208000035484 Cellulite Diseases 0.000 description 1
102000016917 Complement C1 Human genes 0.000 description 1
108010028774 Complement C1 Proteins 0.000 description 1
XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
101710121417 Envelope glycoprotein Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
208000002476 Falciparum Malaria Diseases 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
244000303040 Glycyrrhiza glabra Species 0.000 description 1
235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
208000005794 Hairy Leukoplakia Diseases 0.000 description 1
101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
235000017443 Hedysarum boreale Nutrition 0.000 description 1
235000007858 Hedysarum occidentale Nutrition 0.000 description 1
206010019860 Hereditary angioedema Diseases 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
108010054710 IMREG-1 Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
108010005714 Interferon beta-1b Proteins 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
241000867725 Mucilago Species 0.000 description 1
ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000001388 Opportunistic Infections Diseases 0.000 description 1
208000007027 Oral Candidiasis Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
244000131316 Panax pseudoginseng Species 0.000 description 1
206010049752 Peau d'orange Diseases 0.000 description 1
108010071384 Peptide T Proteins 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
201000011336 Plasmodium falciparum malaria Diseases 0.000 description 1
108010033737 Pokeweed Mitogens Proteins 0.000 description 1
230000007022 RNA scission Effects 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
108010052104 Viral Regulatory and Accessory Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
241000713325 Visna/maedi virus Species 0.000 description 1
ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
231100000230 acceptable toxicity Toxicity 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
210000001132 alveolar macrophage Anatomy 0.000 description 1
UAZIZEMIKKIBCA-TYVGYKFWSA-N amphotericin B methyl ester Chemical compound O([C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@H]([C@H](C1)O2)C(=O)OC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N)[C@@H]1O UAZIZEMIKKIBCA-TYVGYKFWSA-N 0.000 description 1
229940094957 androgens and estrogen Drugs 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
VFBJEDFCUUCMBQ-UHFFFAOYSA-O azanium;sodium;antimony(3+);oxygen(2-);tungsten Chemical compound [NH4+].[O-2].[Na+].[Sb+3].[W] VFBJEDFCUUCMBQ-UHFFFAOYSA-O 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
229940021459 betaseron Drugs 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
238000001815 biotherapy Methods 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
230000006931 brain damage Effects 0.000 description 1
231100000874 brain damage Toxicity 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000036232 cellulite Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
230000024203 complement activation Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
208000024386 fungal infectious disease Diseases 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229910052732 germanium Inorganic materials 0.000 description 1
GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
208000008605 glucosephosphate dehydrogenase deficiency Diseases 0.000 description 1
239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
231100001261 hazardous Toxicity 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
230000000423 heterosexual effect Effects 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
238000003125 immunofluorescent labeling Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
108010006088 interferon alfa-n1 Proteins 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
231100001022 leukopenia Toxicity 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000009245 menopause Effects 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
210000002864 mononuclear phagocyte Anatomy 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
229960003086 naltrexone Drugs 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
238000001668 nucleic acid synthesis Methods 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
229940127073 nucleoside analogue Drugs 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
206010030979 oral hairy leukoplakia Diseases 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
229960002036 phenytoin Drugs 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000011552 rat model Methods 0.000 description 1
108010043277 recombinant soluble CD4 Proteins 0.000 description 1
239000006215 rectal suppository Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
102000037983 regulatory factors Human genes 0.000 description 1
108091008025 regulatory factors Proteins 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
229940064914 retrovir Drugs 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
206010040872 skin infection Diseases 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
230000017960 syncytium formation Effects 0.000 description 1
239000011885 synergistic combination Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
YFNGWGVTFYSJHE-UHFFFAOYSA-K trisodium;phosphonoformate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)C([O-])=O.OP(O)(=O)C([O-])=O.OP(O)(=O)C([O-])=O YFNGWGVTFYSJHE-UHFFFAOYSA-K 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
235000020138 yakult Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Natural Medicines & Medicinal Plants (AREA)
Molecular Biology (AREA)
Mycology (AREA)
Microbiology (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Alternative & Traditional Medicine (AREA)
Biotechnology (AREA)
Botany (AREA)
Medical Informatics (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

SE8801406A 1987-04-16 1988-04-15 Användning av 17-ketosteroider, eventuellt åtföljande eller i kombination med ett immunomoduleringsmedel eller ett antiviralt medel, för framställning av ett läkemedel för användning vid profylax och terapi av en retroviral infektion SE503482C2 (sv)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IE99787		1987-04-16
IE228987		1987-08-27

Publications (3)

Publication Number	Publication Date
SE8801406D0 SE8801406D0 (sv)	1988-04-15
SE8801406L SE8801406L (sv)	1988-10-17
SE503482C2 true SE503482C2 (sv)	1996-06-24

Family

ID=26319024

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8801406A SE503482C2 (sv)	1987-04-16	1988-04-15	Användning av 17-ketosteroider, eventuellt åtföljande eller i kombination med ett immunomoduleringsmedel eller ett antiviralt medel, för framställning av ett läkemedel för användning vid profylax och terapi av en retroviral infektion

Country Status (23)

Country	Link
US (1)	US4956355A (de)
JP (1)	JP2577771B2 (de)
KR (1)	KR960014988B1 (de)
AT (1)	AT401470B (de)
AU (1)	AU608824B2 (de)
BE (1)	BE1004315A5 (de)
CA (1)	CA1325594C (de)
CH (1)	CH675358A5 (de)
DE (1)	DE3812595C2 (de)
DK (1)	DK175582B1 (de)
FI (1)	FI881773A7 (de)
FR (1)	FR2615394B1 (de)
GB (1)	GB2204237B (de)
GR (1)	GR1002240B (de)
IL (1)	IL86089A (de)
IT (1)	IT1227073B (de)
LU (1)	LU87202A1 (de)
NL (1)	NL194728C (de)
NZ (1)	NZ224272A (de)
OA (1)	OA08729A (de)
PH (1)	PH25907A (de)
PT (1)	PT87259B (de)
SE (1)	SE503482C2 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3687692T2 (de) *	1985-11-13	1993-05-19	Japan Res Dev Corp	Geschlechtshormone zur behandlung von immun-mangel-krankheiten.
US5356900A (en) *	1986-10-07	1994-10-18	Bernard Bihari	Method of treating chronic herpes virus infections using an opiate receptor antagonist
US6638894B1 (en) *	1987-01-09	2003-10-28	Lucent Technologies Inc.	Devices and systems based on novel superconducting material
US5204113A (en) *	1987-04-09	1993-04-20	Fisons Plc	Pharmaceutical compositions containing pentamidine
ATE77947T1 (de) *	1987-04-09	1992-07-15	Fisons Plc	Pentamidin enthaltende pharmazeutische zusammensetzungen.
US5077284A (en) *	1988-12-30	1991-12-31	Loria Roger M	Use of dehydroepiandrosterone to improve immune response
US5407684A (en) *	1988-12-30	1995-04-18	Virginia Commonwealth University	Use of DHEA as a medicinal
CA2066716A1 (en) *	1989-09-25	1991-03-26	Raymond A. Daynes	Use of steroid hormones in compositions for inducing t cell lymphokine production
US5562910A (en) *	1989-09-25	1996-10-08	University Of Utah Research Foundation	Vaccine compositions and method for enhancing an immune response
US5824313A (en) *	1989-09-25	1998-10-20	University Of Utah Research Foundation	Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5837269A (en) *	1989-09-25	1998-11-17	University Of Utah Research Foundation	Vaccine compositions and method for enhancing an immune response
US5518725A (en) *	1989-09-25	1996-05-21	University Of Utah Research Foundation	Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5753237A (en) *	1989-09-25	1998-05-19	University Of Utah Research Foundation	Method for augmenting immunological responses
US5162361A (en) *	1990-04-10	1992-11-10	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Method of treating diseases associated with elevated levels of interleukin 1
US5292730A (en) *	1990-08-29	1994-03-08	Humanetics Corporation	Modulation of immune system with Δ5-androstenes
IE63418B1 (en) *	1990-09-10	1995-04-19	Elan Corp Plc	Progression risk of HIV by assay of dehydroepiandrosterone in body fluid
US5206008A (en) *	1991-04-15	1993-04-27	Virginia Commonwealth University	Enhancement of immune response
JPH05317041A (ja) *	1991-06-05	1993-12-03	Nippon Oil Co Ltd	動物細胞増殖促進剤及び無血清培地
US5230897A (en) *	1991-10-31	1993-07-27	G. D. Searle & Co.	Transdermal pentamidine
JPH07504198A (ja) *	1992-02-24	1995-05-11	イーストカロライナユニバーシティ	デヒドロエピアンドロステロンおよびその類縁体を用いる処置によって発癌を抑制する方法
JPH07506372A (ja) *	1992-05-01	1995-07-13	ユニバーシティ・オブ・ユタ	インビボでのｉｌ−６産生を調節する組成物および方法
US5346997A (en) *	1992-08-26	1994-09-13	Murphy James G	Agents for complexing sodium under biological conditions
FR2696934B1 (fr) *	1992-10-20	1995-06-02	Conservatoire Nal Arts Metiers	Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
US5776923A (en) *	1993-01-19	1998-07-07	Endorecherche, Inc.	Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
AU5855794A (en) *	1993-01-19	1994-08-15	Endorecherche Inc.	Therapeutic uses and delivery systems of dehydroepiandrosterone
US5439899A (en) *	1993-03-10	1995-08-08	Purdue Research Foundation	Cosalane and related compounds having activity against aids and aids-related infections
US5407927A (en) *	1993-04-16	1995-04-18	The Regents Of The University Of California	Treatment of mild depression and restoration of IGF-I levels in aging by dehydroepiandrosterone
US5466465A (en) *	1993-12-30	1995-11-14	Harrogate Holdings, Limited	Transdermal drug delivery system
JPH10503921A (ja) *	1994-04-05	1998-04-14	パーデュリサーチファウンデーション	診断並びに治療におけるターゲットとしてのｎａｄｈオキシダーゼ
US5660835A (en) *	1995-02-24	1997-08-26	East Carolina University	Method of treating adenosine depletion
US20020032160A1 (en) *	1995-02-24	2002-03-14	Nyce Jonathan W.	Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
US7893044B2 (en) *	1995-02-24	2011-02-22	Epigenesis Pharmaceutical, Inc.	Composition and method for altering levels of or sensitivity to adenosine with analogs of dehydroepiandrosterone
US6162450A (en) *	1995-05-15	2000-12-19	Avon Products, Inc.	Uses of ascorbyl-phosphoryl-cholesterol and compositions for practicing same
CA2244535A1 (en) *	1995-05-15	2000-01-30	Avon Products, Inc.	Novel uses for ascorbyl-phosphoryl-cholesterol in topical compositions
US5736537A (en) *	1995-09-12	1998-04-07	Estee Lauder, Inc.	Dehydroep:androsterone sailcylate useful against skin atrophy
EP0843554B1 (de) *	1996-05-14	1999-12-08	Avon Products, Inc.	Ascorbyl-phosphorylcholesterol
GB9612990D0 (en) *	1996-06-20	1996-08-21	Stanford Rock Ltd	Compositions and methods for the treatment of chronic infections
US5885977A (en) *	1997-01-15	1999-03-23	Humanetics Corporation	Use of Δ5 androstenes in the treatment of HIV wasting syndrome
US5902593A (en) *	1997-10-01	1999-05-11	Kent; Frances B.	Topically applied personal lubricant containing benzalkonium chloride as the active ingredient
US20060079492A1 (en) *	1999-10-25	2006-04-13	Ahlem Clarence N	Compositions and treatment methods
US20070129282A1 (en) *	1998-11-24	2007-06-07	Ahlem Clarence N	Pharmaceutical treatments and compositions
US6667299B1 (en) *	2000-03-16	2003-12-23	Hollis-Eden Pharmaceuticals, Inc.	Pharmaceutical compositions and treatment methods
OA11716A (en) *	1998-11-24	2005-01-25	Hollis Eden Pharmaceuticals	Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatmentof hepatitis C virus and other togaviruses.
IL142941A0 (en) *	1998-11-24	2002-04-21	Holis Eden Pharmaceuticals Inc	Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of african and american trypanosomiasis
US20030083231A1 (en) *	1998-11-24	2003-05-01	Ahlem Clarence N.	Blood cell deficiency treatment method
WO2000032176A2 (en) *	1998-11-27	2000-06-08	Hollis-Eden Pharmaceuticals, Inc.	Use of 17-ketosteroids for the treatment of toxoplasmosis and cryptosporidosis
CA2365081A1 (en) *	1999-03-23	2000-09-28	Hollis-Eden Pharmaceuticals, Inc.	Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone
EP1422234A3 (de) *	1999-03-23	2010-12-08	Harbor BioSciences, Inc.	Immunomodulierende Steroide, Insbesondere Die Hemihydrat Von 16.alpha.-bromoepiandrosteronen
FR2792201B1 (fr) *	1999-04-15	2001-11-02	Donatien Mavoungou	Procede du renforcement immunitaire et du developpement d'un transporteur lipidique pour une therapie genique anti-vih et anti-bacterienne
US20050245502A1 (en) *	1999-08-23	2005-11-03	Phoenix Biosciences	Treatments for viral infections
US7479498B2 (en) *	1999-08-23	2009-01-20	Phoenix Biosciences, Inc.	Treatments for viral infections
PT1955700E (pt)	1999-09-30	2011-05-04	Harbor Biosciences Inc	Tratamento terap?utico de doen?as associadas ao receptor de androg?nios
AU2002303425A1 (en) *	2001-04-24	2002-11-05	Epigenesis Pharmaceuticals, Inc.	Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
EP1553954A4 (de) *	2002-06-17	2009-12-23	Epigenesis Pharmaceuticals Llc	Dihydrat-dehydroepiandrosteron und verfahren zur behandlung von asthma oder chronisch obstruktiver lungenerkrankung mit zusammensetzungen daraus
US20050101545A1 (en) *	2003-07-31	2005-05-12	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050026880A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050043282A1 (en) *	2003-07-31	2005-02-24	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) *	2003-07-31	2009-11-19	Robinson Cynthia B	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026890A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20090317476A1 (en) *	2003-07-31	2009-12-24	Robinson Cynthia B	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090285899A1 (en) *	2003-07-31	2009-11-19	Robinson Cynthia B	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) *	2003-07-31	2005-02-17	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026848A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) *	2003-07-31	2009-10-22	Robinson Cynthia B	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) *	2003-07-31	2009-12-03	Robinson Cynthia B	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) *	2003-07-31	2005-05-26	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4005200A (en) *	1975-07-17	1977-01-25	Kanebo, Ltd.	Method for improving the maturity of the parturient canal and the sensitivity to oxytocin
SE439586B (sv) *	1975-09-05	1985-06-24	Kanebo Ltd	Sett att framstella ett stabilt farmaceutiskt torrpreparat av ett alkalimetallsalt av dehydroepiandrosteronsulfat
US4496556A (en) *	1982-08-16	1985-01-29	Norman Orentreich	Topical applications for preventing dry skin
US4518595A (en) *	1983-07-19	1985-05-21	The Jackson Laboratory	Method for treating diabetes using DHEA compounds
IE72193B1 (en) *	1983-08-02	1997-03-26	Res Corp Technologies Inc	Steroids useful as anti-cancer anti-obesity anti-hyperglycemic anti-autoimmune and anti-hypercholesterolemic agents
US4507289A (en) *	1983-12-28	1985-03-26	Progenics, Inc.	Treatment of diabetes and other symptoms of hypercorticoidism using a synergistic combination of etiocholanolones and estrogen
US4602008A (en) *	1984-12-14	1986-07-22	Progenics, Inc.	Alkylated etiocholanolones and use as an anti-diabetic, anti-obesity and erythropoietic agent
US4724232A (en) *	1985-03-16	1988-02-09	Burroughs Wellcome Co.	Treatment of human viral infections
US4628052A (en) *	1985-05-28	1986-12-09	Peat Raymond F	Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities
NL8502571A (nl) *	1985-09-20	1987-04-16	Akzo Nv	Steroiden met immunomodulerende eigenschappen.
DE3687692T2 (de) *	1985-11-13	1993-05-19	Japan Res Dev Corp	Geschlechtshormone zur behandlung von immun-mangel-krankheiten.

1988
- 1988-04-11 NL NL8800926A patent/NL194728C/nl not_active IP Right Cessation
- 1988-04-14 PH PH36798A patent/PH25907A/en unknown
- 1988-04-14 GB GB8808864A patent/GB2204237B/en not_active Expired - Fee Related
- 1988-04-15 CA CA000564245A patent/CA1325594C/en not_active Expired - Fee Related
- 1988-04-15 FI FI881773A patent/FI881773A7/fi not_active IP Right Cessation
- 1988-04-15 PT PT87259A patent/PT87259B/pt not_active IP Right Cessation
- 1988-04-15 OA OA59333A patent/OA08729A/xx unknown
- 1988-04-15 DK DK198802081A patent/DK175582B1/da not_active IP Right Cessation
- 1988-04-15 LU LU87202A patent/LU87202A1/fr unknown
- 1988-04-15 IT IT8847858A patent/IT1227073B/it active
- 1988-04-15 BE BE8800428A patent/BE1004315A5/fr not_active IP Right Cessation
- 1988-04-15 JP JP63093293A patent/JP2577771B2/ja not_active Expired - Fee Related
- 1988-04-15 AT AT0098488A patent/AT401470B/de not_active IP Right Cessation
- 1988-04-15 DE DE3812595A patent/DE3812595C2/de not_active Expired - Fee Related
- 1988-04-15 KR KR1019880004283A patent/KR960014988B1/ko not_active Expired - Fee Related
- 1988-04-15 US US07/182,480 patent/US4956355A/en not_active Expired - Lifetime
- 1988-04-15 FR FR8805043A patent/FR2615394B1/fr not_active Expired - Fee Related
- 1988-04-15 IL IL86089A patent/IL86089A/xx not_active IP Right Cessation
- 1988-04-15 GR GR880100248A patent/GR1002240B/el not_active IP Right Cessation
- 1988-04-15 CH CH1393/88A patent/CH675358A5/fr not_active IP Right Cessation
- 1988-04-15 SE SE8801406A patent/SE503482C2/sv not_active IP Right Cessation
- 1988-04-15 NZ NZ224272A patent/NZ224272A/xx unknown
- 1988-04-15 AU AU14678/88A patent/AU608824B2/en not_active Ceased

Also Published As

Publication number	Publication date
JP2577771B2 (ja)	1997-02-05
IT8847858A0 (it)	1988-04-15
GB8808864D0 (en)	1988-05-18
NL8800926A (nl)	1988-11-16
NL194728C (nl)	2003-01-07
JPS6425722A (en)	1989-01-27
DK208188D0 (da)	1988-04-15
DE3812595A1 (de)	1988-10-27
LU87202A1 (fr)	1988-11-17
IL86089A (en)	1992-11-15
BE1004315A5 (fr)	1992-11-03
FR2615394A1 (fr)	1988-11-25
KR960014988B1 (ko)	1996-10-23
CA1325594C (en)	1993-12-28
DK208188A (da)	1988-10-17
FI881773A7 (fi)	1988-10-17
NZ224272A (en)	1991-09-25
GR880100248A (el)	1989-01-31
NL194728B (nl)	2002-09-02
SE8801406D0 (sv)	1988-04-15
US4956355A (en)	1990-09-11
PH25907A (en)	1991-12-19
IL86089A0 (en)	1988-09-30
AU608824B2 (en)	1991-04-18
CH675358A5 (de)	1990-09-28
AT401470B (de)	1996-09-25
AU1467888A (en)	1988-10-20
FI881773A0 (fi)	1988-04-15
KR880012233A (ko)	1988-11-26
IT1227073B (it)	1991-03-14
SE8801406L (sv)	1988-10-17
FR2615394B1 (fr)	1994-09-23
PT87259A (pt)	1988-05-01
GB2204237A (en)	1988-11-09
GB2204237B (en)	1991-02-06
ATA98488A (de)	1996-02-15
OA08729A (en)	1989-03-31
PT87259B (pt)	1992-08-31
DE3812595C2 (de)	1997-07-03
DK175582B1 (da)	2004-12-13
GR1002240B (en)	1996-04-22

Legal Events

Date	Code	Title	Description
2006-12-19	NUG	Patent has lapsed

Publication	Publication Date	Title
SE503482C2 (sv)	1996-06-24	Användning av 17-ketosteroider, eventuellt åtföljande eller i kombination med ett immunomoduleringsmedel eller ett antiviralt medel, för framställning av ett läkemedel för användning vid profylax och terapi av en retroviral infektion
US5679828A (en)	1997-10-21	Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
Sarin et al.	1987	Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone
US6172110B1 (en)	2001-01-09	Acylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US20210388320A1 (en)	2021-12-16	Differentiation-induced cell population from which undifferentiated cells have been removed, use of same, and method for producing same
Kanmogne et al.	2002	HIV-1 gp120 proteins and gp160 peptides are toxic to brain endothelial cells and neurons: possible pathway for HIV entry into the brain and HIV-associated dementia
HK85789A (en)	1989-11-03	Antiviral nucleosides
CA1339854C (en)	1998-05-05	Viral treatment system
Roberts et al.	1995	N-acetylcysteine enhances antibody-dependent cellular cytotoxicity in neutrophils and mononuclear cells from healthy adults and human immunodeficiency virus-infected patients
US4704357A (en)	1987-11-03	Immortalized T-lymphocyte cell line for testing HTLV-III inactivation
EP0415902B1 (de)	1993-03-17	Sauerstoff- oder schwefelsubstituierte Fettsäureanaloga zur Behandlung retroviraler Infektionen
WO2004028455A2 (en)	2004-04-08	Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
Bergamini et al.	1992	A tetrazolium-based colorimetric assay for quantification of HIV-1-induced cytopathogenicity in monocyte-macrophages exposed to macrophage-colony-stimulating factor
Tsai et al.	1994	Comparison of the efficacy of AZT and PMEA treatment against acute SIVmne infection in macaques
Dore-Duffy	1982	Differential effect of prostaglandins and other products of arachidonic acid metabolism on measles virus replication in Vero cells
Satoh et al.	1990	Absence of natural killer (NK) cell activity against oligodendrocytes in multiple sclerosis
Blakeslee Jr et al.	1985	Human T-Cell Leukemia Virus I Induction by 5-lodo-2′-deoxyuridine and N-Methyl-N′-nitro-N-nitrosoguanidine: Inhibition by Retinoids, l-Ascorbic Acid, and dl-α-Tocopherol
Kristiansen et al.	1991	Effect of Selected Neuroleptic Agents and Stereo‐Isomeric Analogues on Virus and Eukaryotic Cells
NZ236303A (en)	1997-07-27	17-ketosteroids, manufacture of aids medicament
US20070258970A1 (en)	2007-11-08	Methods for Inhibiting Hiv and Other Viral Infections by Modulating Ceramide Metabolism
WO1994004139A1 (en)	1994-03-03	Treatment of human viral infections
AU735990B2 (en)	2001-07-26	Amino sugars and glycoproteins
Sarin et al.	1987	Lymphadenopathy-Associated Virus) by